Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Meet Incoming Rheumatology Research Foundation President Abby Abelson, MD, FACR

Kelly Tyrrell  |  December 20, 2017

When Abby Abelson, MD, FACR, chair of the Department of Rheumatology and Immunologic Disease at Cleveland Clinic, was in medical school, she enjoyed nearly every one of her rotations. But it was the rheumatology patients who inspired her the most. “I saw they had challenges in their lives that they were able to triumph over,”…

Anthem to Reduce E/M Reimbursement When Billed with Modifier 25

From the College  |  December 20, 2017

Anthem Blue Cross recently announced changes to its reimbursement policies for modifier 25. As of Jan. 1, 2018, Anthem plans in California, Connecticut, Kentucky, Maine, Nevada, New Hampshire, Ohio and Wisconsin will reduce reimbursement for evaluation and management (E/M) services by 50% when billed with modifier 25. This policy will expand to Missouri on Feb….

Legislative Successes in 2017: Rheumatologists lead the push in Congress for access to care, research funding, transparency in drug pricing

Larry Beresford  |  December 20, 2017

SAN DIEGO—The 2017 ACR/ARHP Annual Meeting, Nov. 3–8, presented opportunities to highlight its 2017 legislative advocacy victories, some of which were resolved just weeks before the conference began, as well as issues that are still outstanding. In the session, Legislative & Regulatory Update 2017, Angus Worthing, MD, chair of the ACR’s Government Advocacy Committee and…

Rheumatology Coding Corner Answers: 2017 End-of-Year Quiz

From the College  |  December 19, 2017

Take the challenge. 1. B—No. CPT 99358, prolonged evaluation and management service can be billed before or after direct patient care, first hour or 99539 —each additional 30 minutes (list separately in addition to code for prolonged service). This code cannot be used to bill a higher level E/M visit code. According to 2017 CPT:…

Rheumatology Coding Corner Questions: 2017 End-of-Year Quiz

From the College  |  December 19, 2017

1. A 68-year-old new female patient has an appointment to see the rheumatologist in four days. The patient has her medical records sent over from her primary care physician, neurologist and endocrinologist for the rheumatologist to review prior to the visit. Upon receipt, the rheumatologist spends 55 minutes reviewing the records and making notes. Can…

ARHP Master Designation Award Will Debut at the 2018 ACR/ARHP Annual Meeting

Elizabeth A. Schlenk, PhD, RN, FAAN, & Afton L. Hassett, PsyD  |  December 19, 2017

The ACR Board of Directors approved the ARHP Master Designation at its August 2017 meeting. The first two ARHP Master Designation awardees will be honored at the ACR/ARHP Annual Meeting in Chicago on Oct. 20, 2018. Recognition as a Master of the ARHP is one of the highest honors that the ARHP bestows to members….

Rheumatologist Channels Military Aspirations into Role with U.S. Navy Reserve

Carol Patton  |  December 19, 2017

In 2010, Thomas Bartow, MD, FACP, finally ran out of excuses. Ever since high school, he had wanted to join the military. But too many things got in the way—like attending medical school at State University of New York at Stony Brook. After graduation in 1980, he performed his residency in internal medicine at Rush-Presbyterian-St….

Does MRI Differentiate Osteoarthritis and Meniscal Tear in Knee Pain?

Kelly April Tyrrell  |  December 19, 2017

When a young patient arrives at a clinic complaining of knee pain with clicking or popping, a meniscal tear is often the culprit. “In young [people], there’s a pretty classic presentation of meniscal tear, with clicking and other mechanical symptoms, because the tear rubs up against different tissues,” says Jeffrey Katz, MD, MSc, a rheumatologist…

Long-Term Benefits, Risks of Biologic Disease-Modifying Anti-Rheumatic Drugs in Patients with RA

Nan Yang, PharmD, & Kurt Oelke, MD, on behalf of the ARHP Practice Committee  |  December 19, 2017

Two decades have passed since the first biologic disease-modifying anti-rheumatic drug (bDMARD) was approved. Studies on the long-term use of biologics in different disease states, such as for cardiovascular disease (CVD) and malignancy, as well as for knee/hip replacement, reveal some encouraging news. In clinical trials, bDMARDs have been shown to increase the risk of…

Rheumatology Drug Updates: Hip Fracture Rates After Bisphosphonate Drug Holidays, Plus More on Golimumab, Ustekinumab

Michele B. Kaufman, PharmD, BCGP  |  December 19, 2017

Bisphosphonate Drug Holidays Drug holidays are common for patients on bisphosphonate therapy. Often, these breaks in treatment are related to known U.S. Food and Drug Administration (FDA) warnings and drug class adverse effects. Currently, data on fracture risk related to drug holidays are limited. In recent research highlighted at the 2017 ACR/ARHP Annual Meeting ,…

  • « Previous Page
  • 1
  • …
  • 376
  • 377
  • 378
  • 379
  • 380
  • …
  • 819
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences